Repository logo
 
Publication

HER2-Targeted immunotherapy and combined protocols showed promising antiproliferative effects in feline mammary carcinoma cell-based models

2021-04-21Journal article Open access
Simple item page
dc.contributor.authorGameiro, Andreia
dc.contributor.authorNascimento, Catarina
dc.contributor.authorCorreia, Jorge Manuel de Jesus
dc.contributor.authorFerreira, Fernando
dc.date.accessioned2022-02-05T22:52:11Z
dc.date.available2022-02-05T22:52:11Z
dc.date.issued2021-04-21
dc.descriptionResearch Areas: Oncologypt_PT
dc.description.abstractABSTRACT - Feline mammary carcinoma (FMC) is a highly prevalent tumor, showing aggressive clinicopathological features, with HER2-positive being the most frequent subtype. While, in human breast cancer, the use of anti-HER2 monoclonal antibodies (mAbs) is common, acting by blocking the extracellular domain (ECD) of the HER2 protein and by inducing cell apoptosis, scarce information is available on use these immunoagents in FMC. Thus, the antiproliferative effects of two mAbs (trastuzumab and pertuzumab), of an antibody–drug conjugate compound (T-DM1) and of combined treatments with a tyrosine kinase inhibitor (lapatinib) were evaluated on three FMC cell lines (CATMT, FMCm and FMCp). In parallel, the DNA sequence of the her2 ECD (subdomains II and IV) was analyzed in 40 clinical samples of FMC, in order to identify mutations, which can lead to antibody resistance or be used as prognostic biomarkers. Results obtained revealed a strong antiproliferative effect in all feline cell lines, and a synergistic response was observed when combined therapies were performed. Additionally, the mutations found were not described as inducing resistance to therapy in breast cancer patients. Altogether, our results suggested that anti-HER2 mAbs could become useful in the treatment of FMC, particularly, if combined with lapatinib, since drug-resistance seems to be rare.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationGameiro A, Nascimento C, Correia J, Ferreira F. 2021. HER2-Targeted immunotherapy and combined protocols showed promising antiproliferative effects in feline mammary carcinoma cell-based models. Cancers 13(9):2007. Doi: 10.3390/cancers13092007pt_PT
dc.identifier.doi10.3390/cancers13092007pt_PT
dc.identifier.eissn2072-6694
dc.identifier.urihttp://hdl.handle.net/10400.5/23405
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherMDPIpt_PT
dc.relationC00191rpt_PT
dc.relationCentre for Interdisciplinary Research in Animal Health
dc.relationDeveloping diagnostic tools for feline mammary carcinomas and improving chemotherapy based on HER2 and topoisometase status
dc.relation.publisherversionhttps://www.mdpi.com/2072-6694/13/9/2007pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectFeline mammary carcinomapt_PT
dc.subjectHER2pt_PT
dc.subjectMonoclonal antibodiespt_PT
dc.subjectCombined therapiespt_PT
dc.subjectTyrosinept_PT
dc.subjectKinase inhibitorspt_PT
dc.subjectFeline her2 mutationspt_PT
dc.titleHER2-Targeted immunotherapy and combined protocols showed promising antiproliferative effects in feline mammary carcinoma cell-based modelspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardTitleCentre for Interdisciplinary Research in Animal Health
oaire.awardTitleDeveloping diagnostic tools for feline mammary carcinomas and improving chemotherapy based on HER2 and topoisometase status
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/3599-PPCDT/PTDC%2FCVT-EPI%2F3638%2F2014/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F00276%2F2020/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT//SFRH%2FBD%2F132260%2F2017/PT
oaire.citation.conferencePlaceBasel, Switzerlandpt_PT
oaire.citation.titleCancerspt_PT
oaire.fundingStream3599-PPCDT
oaire.fundingStream6817 - DCRRNI ID
person.familyNameGameiro
person.familyNameGaspar do Nascimento
person.familyNameJesus Correia
person.familyNameFerreira
person.givenNameAndreia
person.givenNameAna Catarina
person.givenNameJorge Manuel
person.givenNameFernando António da Costa
person.identifier.ciencia-idB718-5199-AA36
person.identifier.ciencia-id7311-54F2-A545
person.identifier.ciencia-idF81F-D7D4-57C5
person.identifier.orcid0000-0002-1602-3552
person.identifier.orcid0000-0002-1909-4540
person.identifier.orcid0000-0001-5765-576X
person.identifier.scopus-author-id7202364133
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication56cf4b8e-cfd8-4609-8d16-3a698b9cc3fb
relation.isAuthorOfPublicatione35637f2-a72d-4480-9b4c-950509284cc2
relation.isAuthorOfPublicationbc5cb57b-d601-4020-9adb-ee4cb0996dc7
relation.isAuthorOfPublication84ebf7d6-d393-4bf7-85f5-58a909ce1ff0
relation.isAuthorOfPublication.latestForDiscovery84ebf7d6-d393-4bf7-85f5-58a909ce1ff0
relation.isProjectOfPublicationabc0808c-ecaf-4943-a80f-e0518090d048
relation.isProjectOfPublication8563a044-0c86-49a8-a275-8b1bb62cc0d8
relation.isProjectOfPublicationb50dfa7d-c2d8-4d9c-bd55-fb3c9afb9893
relation.isProjectOfPublication.latestForDiscovery8563a044-0c86-49a8-a275-8b1bb62cc0d8

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
HER2-Targeted Immunotherapy and Combined Protocols Showed Promising Antiproliferative Effects in Feline Mammary Carcinoma Cell-Based Models.pdf
Size:
2.91 MB
Format:
Adobe Portable Document Format
Download

Collections

CIISA - Artigos em revistas internacionais